Loading...
•
Jun 30, 2023
Dynavax Q2 2023 Earnings Report
Dynavax reported second quarter 2023 financial results, highlighted by record HEPLISAV-B vaccine revenue and raised full-year revenue guidance.
Key Takeaways
Dynavax reported total revenues of $60.2 million for the second quarter of 2023, including record HEPLISAV-B vaccine net product revenue of $56.4 million, a 73% year-over-year increase. The company raised its full year HEPLISAV-B net product revenue guidance to $200 - $215 million. Cash and investments increased to $682 million at quarter end.
Generated record quarterly HEPLISAV-B® vaccine net product revenue of $56 million, a 73% year-over-year increase
Full year HEPLISAV-B net product revenue guidance raised to $200 - $215 million, compared to prior range of $165 - $185 million
Cash and investments increased to $682 million at quarter end; expects positive free cash flow for full year
HEPLISAV-B total market share increased to approximately 39%, compared to approximately 32% at the end of the second quarter of 2022.
Revenue by Segment
Forward Guidance
Dynavax revised its full year 2023 financial guidance.
Positive Outlook
- Raising HEPLISAV-B net product revenue between approximately $200 - $215 million
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...